2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study
Alison Stopeck(National Cancer Centre Japan), Guenther G. Steger(Mount Vernon Hospital), Roger Dansey(Memorial Sloan Kettering Cancer Center), Yasuyuki Fujiwara, María Eugenia Ibarrarán Viniegra(National Cancer Centre Japan), J.J. Body(Université Libre de Bruxelles), Ada Braun(Amgen (United States)), Allan Lipton(American Society of Clinical Oncology), Michelle Fan(National Cancer Centre Japan)
Cited by 84
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k